Penumbra Reports Q4 EPS of $0.97, Sales of $315.52M; Biomarin EPS at $0.92, Sales $747.31M; PRA Group EPS $0.47

Penumbra Inc. (NYSE:PEN) reported its fourth-quarter earnings, posting an adjusted earnings per share (EPS) of $0.97, surpassing the estimate of $0.90. The company's sales reached $315.52 million, exceeding the forecast of $311.55 million. Following the earnings announcement, several analysts provided updates on Penumbra's stock. Baird maintained an 'Outperform' rating while raising its price target to $328. Morgan Stanley kept an 'Equal-Weight' rating and increased its price target to $260. Wells Fargo and Piper Sandler both maintained 'Overweight' ratings, with price targets raised to $305 and $330, respectively. Additionally, Biomarin Pharmaceutical (NASDAQ:BMRN) reported an adjusted EPS of $0.92 for the fourth quarter, beating the estimate of $0.53, with sales of $747.31 million, also above expectations of $713.44 million. The company noted sales of its Roctavian product at $11 million for the fourth quarter and $26 million for the entire year, while Voxzogo sales reached $208 million in the quarter. PRA Group (NASDAQ:PRAA) also reported a fourth-quarter EPS of $0.47, exceeding the estimate of $0.44, with sales of $293.23 million, beating the forecast of $275.81 million.